A Randomized, Open-Label, Repeat Dosing (7 days), Four-Period Crossover Study to Compare the Pharmacokinetics, Efficacy and Safety of Tiotropium Bromide Delivered via Breath Actuated Inhaler (BAI), SPIRIVA HandiHaler and Respimat Soft Mist Inhaler (SMI) in Subjects with Chronic Obstructive Pulmonary Disease (COPD)

Trial Profile

A Randomized, Open-Label, Repeat Dosing (7 days), Four-Period Crossover Study to Compare the Pharmacokinetics, Efficacy and Safety of Tiotropium Bromide Delivered via Breath Actuated Inhaler (BAI), SPIRIVA HandiHaler and Respimat Soft Mist Inhaler (SMI) in Subjects with Chronic Obstructive Pulmonary Disease (COPD)

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2013

At a glance

  • Drugs Tiotropium bromide (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacokinetics
  • Most Recent Events

    • 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Jul 2013 Planned end date changed from 1 Jun 2013 to 1 Jul 2013 as reported by ClinicalTrials.gov.
    • 26 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top